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The second NMA did not report the definition used; instead, the eligibility criteria 
were defined in terms of the treatments assessed in the randomized controlled trials 
(RCTs). The eligibility criteria adopted in each RCT and the resulting patient popula-
tion characteristics were collected in order to assess comparability among the trials 
in each NMA. Results: The RCTs selected in each of the NMAs adopted diverse 
eligibility criteria based on body surface area (BSA), psoriasis area and severity index 
(PASI) score and exposure or failure to previous therapies. Although many of the 
trials adopted eligibility criteria that aligned with clinical guideline definitions of 
moderate to severe PsO as BSA above 10% and PASI above 10, the resulting ‘moder-
ate to severe’ populations showed wide variation in their baseline characteristics. 
Analogous differences in placebo responses were observed. For example, baseline 
PASI scores ranged from 14 to 23, while the proportion of patients with a 75% reduc-
tion in the PASI scores at 12 weeks varied from 2% to 18% among the trials in each 
NMA. ConClusions: The current definitions of ‘moderate to severe’ PsO do not 
seem enough to guarantee similarity in severity across trials, which may lead to 
imbalance in the distribution of potential effect modifiers across comparisons, and 
consequent bias in the NMA estimates. In the absence of better characterization of 
the patient population, adjusting for baseline risk is advisable.
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objeCtives: Children undergoing surgery often experience anxiety, exhibit nega-
tive behaviors and suffer postoperative pain. Previous studies showed inconsistent 
findings in the effects of therapeutic play intervention on children’s perioperative 
anxiety, negative behaviors and postoperative pain. This study aimed to exam-
ine the effectiveness of a therapeutic play intervention on perioperative anxiety, 
negative emotional manifestation and postoperative pain in children undergoing 
inpatient elective surgery. Methods: A randomized controlled trial with two-
group pre- and post-tests study design was conducted. A total of 106 eligible chil-
dren (6-14 years old) were recruited and randomly allocated to either a control 
group (receiving routine care) (n = 53) or an experimental group (receiving one-
hour therapeutic play intervention in addition to routine care) (n = 53). Outcome 
measures included children’s anxiety, emotional manifestation and postoperative 
pain which were conducted at baseline (3-7 days before the operation), on the 
day of surgery, and around 24 hours after surgery. Repeated measures ANCOVA 
and univariate analysis of covariance were used to analyse the data. Results: 
Children in the experimental group demonstrated no superior result in periop-
erative anxiety (p > 0.05), but indicated significantly fewer negative emotional 
manifestations (p < 0.01) and less postoperative pain (p < 0.01) as compared with 
those in the control group. ConClusions: The therapeutic play intervention is 
superior to usual care in reducing negative behaviors and postoperative pain in 
children undergoing inpatient elective surgery. These findings suggest the need 
of providing the therapeutic play intervention for school-aged children who are 
undergoing inpatient elective surgery.
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objeCtives: Chronic low back pain (CLBP) with or without radiculopathy is a major 
expensive, and disabling condition around the globe. Limited safety and efficacy 
data of various analgesics make difficult in prescribing. Present study aimed at 
assessing the efficacy and safety of combination therapy of pregabalin and ami-
triptyline in patients with CLBP in Indian population. Methods: A longitudinal 
prospective observational study was conducted at pain clinic of a public tertiary 
care hospital. Adult patients suffering from low back pain for > 3 months, and who 
received pregabalin (75-150 mg/day) and amitriptyline (10/25 mg/day) were included 
in the study. Data collected for baseline and follow-ups of monthly through hospital 
visits and telephonic contacting until 6 months for VAS; baseline and 6 months for 
Modified Ostwery low back pain Disability questionnaire (MODQ). Percentage of 
patients achieved > 50% of pain reduction by VAS score (0-100) after six months is 
the primary endpoint. Safety and improvement in quality of life after six months 
assessed as secondary endpoint. Analysis done by one way repeated measures 
anova. Results: A total of 198 patients were included in this study with mean age 
of 44.8+12.4 years, 63% are having BMI > 25kg/m2, and duration of pain 30 (12-60) 
months. Magnetic imaging resonance findings have shown disc bulging (43.9%), disc 
herniation (12.6%), spondylosis (11.1%) and other problems. Significant reduction 
in pain was observed p< 0.01 on VAS score after 6 months follow up. VAS&MODQ 
baseline median (IQR) scores found to be 75(60-90)&52(40-60), and after 6 months 
35(20-50)&41(24-53), no improvement in quality of life found p= 0.08. Dry mouth is 
being the commonest adverse event [in 80 (40.4)]. Other adverse events reported 
are headache, constipation, dizziness and postural hypotension. ConClusions: 
Our results suggest that combination of pregabalin and amitriptyline are efficacious 
and safe in managing CLBP.
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MCR was 7 [range: 2-30]. ConClusions: In this observational descriptive study, 
the efficacy of azacitidine for Intermediate-2 and High-risk MDS patients has 
been reported. However, these findings need to be complemented with more 
statistical data, to have a more accurate picture of azacitidine in community practice.
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objeCtives: Obesity is a major health crisis with vast economic and population-
health implications. Effective pharmacological therapies for weight management 
are desirable, yet few have been approved by the Food and Drug Administration 
(FDA) since the withdrawal of fenfluramine/phentermine in the late 1990’s. 
Recently a new product, combination phentermine/topiramate, obtained mar-
keting approval. Both phentermine monotherapy and topiramate monotherapy 
were previously investigated for weight loss, yet only one study compared this 
new combination product to its respective components. The goal of this current 
meta-analysis was to compare the effectiveness of phentermine monotherapy, 
topiramate monotherapy, and phentermine/topiramate combination therapy in 
weight reduction treatment. Methods: Studies were identified from published 
meta-analyses, pharmacological weight loss review articles, and electronic data-
bases including PubMED and ClinicalTrials.gov. Eligible studies were randomized 
placebo-controlled trials with the objective of weight loss assessment. Data from 6 
studies of combination phentermine/topiramate, 10 studies of topiramate mono-
therapy, and 9 studies of phentermine monotherapy were included for analysis. 
Pooled analysis of mean percent weight change was performed using a random 
effects model. Intervention-induced weight loss was assessed and described over-
all and in relation to pooled weight loss estimates of subjects receiving control 
(placebo) treatment. Results: Phentermine/topiramate combination therapy 
had a mean percent weight loss above placebo of 7.18% (95% CI -8.22 to -6.14%), 
a treatment effect larger than the mean percent weight loss above placebo of 
4.57% (95% CI -5.39 to -3.76%) calculated for topiramate monotherapy or the mean 
percent weight loss above placebo of 5.79% (95% CI -6.82 to -4.75%) calculated for 
phentermine monotherapy. ConClusions: Pooled clinical trial data show that 
phentermine/topiramate combination therapy is more effective than topiramate 
monotherapy and phentermine monotherapy in reducing weight. Future studies 
to assess the effectiveness of phentermine/topiramate combination therapy are 
merited to determine if these controlled trial-derived weight loss results translate 
to real-world clinical success.
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objeCtives: Pain is an important driver of quality of life and health care resource 
use, though few treatments are available to effectively treat neuropathic pain. The 
purpose of this study was to characterise the retreatment interval, patch usage 
and clinical effectiveness of the capsaicin 8% patch ‘Qutenza’ (QTZ) when used 
to treat peripheral neuropathic pain in clinical practice. Methods: Interim data 
were available from a prospective, observational study of people with neuropathic 
pain treated with QTZ throughout Europe (n= 340); the ASCEND study. The Numeric 
Pain Rating Scale (NPRS) recorded pain on an integer scale between 0 (no pain) 
and 10 (worst imaginable pain). Time to retreatment was evaluated using the 
Kaplan-Meier method, accounting for right-censored observations. Change 
in pain severity was evaluated using independent sample and paired sam-
ples t-tests. Results: At baseline, the mean NPRS was 6.82 (SD 1.89). At eight 
weeks following first treatment, 43.8% of patients achieved a 30% reduction 
and 24.2% a 50% reduction. In this analysis, 105 (30.9%) patients were retreated 
with QTZ at least once, of which 26 (7.7%) had two re-treatments, and 5 (1.5%) 
had three or more re-treatments. There was no difference in baseline NPRS 
between those that progressed to receiving multiple treatments and those 
treated once (mean NPRS= 6.87 vs. 6.67 units respectively (p= 0.355)). Mean NPRS 
prior to the second application was 5.66 (2.09; p< 0.001), and 5.19 (2.38; p= 0.010) 
prior to subsequent applications. The mean number of patches used at the first, 
second and third applications was 1.18 (0.81), 1.16 (0.75), and 1.19 (1.07), respec-
tively (p= 0.115, p= 0.214). The median time from first to second treatment was 
22 weeks (95% CI 17―27), and from second to third a further 21 weeks (95% CI 
16―26). ConClusions: This study shows that capsaicin 8% patch use and retreat-
ment intervals are stable across successive treatments suggesting consistent 
efficacy.
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objeCtives: To assess the comparability of the trials included in network meta-
analyses (NMAs) comparing biologic treatments in moderate to severe plaque 
psoriasis (PsO). Methods: A systematic literature review identified two recently 
published NMAs. The definition of ‘moderate to severe’ psoriasis adopted by one 
of the NMAs was “having an inadequate response to topical treatments alone and 
either having received prior systemic therapy or being candidate for such therapy”. 
